Literature DB >> 7478583

Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation.

K T Malik1, J I Wallace, S M Ivins, K W Brown.   

Abstract

Expression of the Wilms' tumour suppressor gene, WT1, is tightly regulated during nephrogenesis, and loss of function of its gene product correlates with malignancy. By using luciferase reporter gene constructs containing DNA sequences from the first intron of the WT1 gene, we have identified an antisense WT1 promoter operational in the opposite direction relative to the 5' promoter. Transcription directed by the promoter is negatively regulated by upstream elements, but is activated by expression of WT1. This effect of WT1 is reciprocal to that observed on the 5' promoter, suggesting that antisense promoter activity is involved in WT1 gene regulation. By mimicking expression of the transcript regulated by the antisense promoter, we demonstrate that cellular levels of WT1 can be effectively down-regulated by antisense mRNA complementary to sequences in the first exon of WT1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478583

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Highly expressed genes are associated with inverse antisense transcription in mouse.

Authors:  Andras Györffy; Pawel Surowiak; Zsolt Tulassay; Balazs Györffy
Journal:  J Genet       Date:  2007-08       Impact factor: 1.166

Review 2.  The silence RNA keeps: cis mechanisms of RNA mediated epigenetic silencing in mammals.

Authors:  Cristina Tufarelli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

Review 3.  Making (anti)sense of non-coding sequence conservation.

Authors:  D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

4.  Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients.

Authors:  Sunde Yılmaz Susluer; Cagla Kayabasi; Besra Ozmen Yelken; Aycan Asik; Didem Celik; Tugce Balci Okcanoglu; Suheyla Serin Senger; Cigir Biray Avci; Sukran Kose; Cumhur Gunduz
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

5.  Characterization of multiple alternative RNAs resulting from antisense transcription of the PR264/SC35 splicing factor gene.

Authors:  A Sureau; J Soret; C Guyon; C Gaillard; S Dumon; M Keller; P Crisanti; B Perbal
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

6.  Beckwith-Wiedemann syndrome and uniparental disomy 11p: fine mapping of the recombination breakpoints and evaluation of several techniques.

Authors:  Valeria Romanelli; Heloisa N M Meneses; Luis Fernández; Victor Martínez-Glez; Ricardo Gracia-Bouthelier; Mario F Fraga; Encarna Guillén; Julián Nevado; Esther Gean; Loreto Martorell; Victoria Esteban Marfil; Sixto García-Miñaur; Pablo Lapunzina
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

7.  Structure and organization of the human theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex.

Authors:  M Coggan; L Whitbread; A Whittington; P Board
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

8.  Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors.

Authors:  Laxmi Chilukamarri; Anne L Hancock; Sally Malik; Joanna Zabkiewicz; Jenny A Baker; Alexander Greenhough; Anthony R Dallosso; Tim Hui-Ming Huang; Brigitte Royer-Pokora; Keith W Brown; Karim Malik
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

9.  Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer.

Authors:  Anthony R Dallosso; Anne L Hancock; Sally Malik; Ashreena Salpekar; Linda King-Underwood; Kathy Pritchard-Jones; Jo Peters; Kim Moorwood; Andrew Ward; Karim T A Malik; Keith W Brown
Journal:  RNA       Date:  2007-10-16       Impact factor: 4.942

10.  Deoxyribozymes: new therapeutics to treat central nervous system disorders.

Authors:  Barbara Grimpe
Journal:  Front Mol Neurosci       Date:  2011-09-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.